Search

Your search keyword '"Marit Westman"' showing total 35 results
Start Over Author "Marit Westman"
35 results on '"Marit Westman"'

1. Dietary fibre in relation to asthma, allergic rhinitis and sensitization from childhood up to adulthood

Author

Emmanouela Sdona, Sandra Ekström, Niklas Andersson, Niclas Håkansson, Alicja Wolk, Marit Westman, Marianne vanHage, Inger Kull, Erik Melén, and Anna Bergström

Subjects
allergic rhinitis, asthma, cohort, dietary fibre, sensitization, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Dietary fibre may reduce the risk of allergy. Our aim was to investigate the association between fibre intake in childhood, asthma, allergic rhinitis and IgE sensitization up to adulthood. Methods The individual fibre intake of 2285 participants from the Swedish population‐based birth cohort BAMSE was estimated between 98‐ and 107‐item food frequency questionnaires at ages 8 and 16 years, respectively. At 8, 16 and 24 years, asthma and allergic rhinitis symptoms were assessed by questionnaires, and sensitization to common allergens by serum IgE. Longitudinal associations were analysed by generalized estimating equations, adjusting for potential confounders. Results An inverse overall association was indicated between fibre intake at 8 years and allergic rhinitis symptoms up to 24 years (OR per 5 g/d 0.86; 95% CI 0.77–0.96), particularly in combination with airborne (0.74; 0.62–0.89) and food (0.69; 0.54–0.88) allergen sensitization. Higher fibre intake was also associated with specific allergen sensitization, for example, birch (0.77; 0.67–0.88) and soy (0.68; 0.53–0.87). No association was observed with asthma. Regarding sources, fruit (0.79; 0.67–0.94) and other (potatoes, chips/popcorn, legumes, and nuts, 0.71; 0.50–0.99), but not cereal or vegetable fibre were associated with allergic rhinitis. In additional analyses, including long‐term fibre intake at 8 and 16 years, excluding participants with food‐related allergic symptoms to examine reverse causation, as well as adjusting for antioxidant intake, associations were attenuated and became non‐significant. Conclusion Higher fibre intake in mid‐childhood may be inversely associated with allergic rhinitis and sensitization to specific allergens up to adulthood. However, avoidance of food triggers of allergic symptoms in allergic rhinitis patients may contribute to the protective associations.

Published
2022
Full Text
View/download PDF

2. Male sex is strongly associated with IgE-sensitization to airborne but not food allergens: results up to age 24 years from the BAMSE birth cohort

Author

Erik Melén, Anna Bergström, Inger Kull, Catarina Almqvist, Niklas Andersson, Anna Asarnoj, Magnus P. Borres, Antonis Georgellis, Göran Pershagen, Marit Westman, Marianne van Hage, and Natalia Ballardini

Subjects
Allergen, BAMSE, Birth cohort, Immunoglobulin E, Prevalence, Sensitization, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Up to half of the population in high-income countries has allergen-specific IgE antibodies. However, data regarding sex differences of IgE-sensitization from childhood to adulthood is limited. Objective To explore IgE-sensitization to common foods and airborne allergens in relation to sex over time in a population-based cohort followed up to young adulthood. Methods The Swedish population-based birth cohort BAMSE includes 4089 subjects who have been followed regularly with questionnaires and clinical investigations. A recent 24-year follow-up included 3069 participants (75%). Sera collected at 4, 8, 16 and 24 years were analyzed for IgE-antibodies to 14 common foods and airborne allergens. Results At 24 years sensitization to foods had decreased compared to previous follow-ups affecting 8.4%, while sensitization to airborne allergens was more common, affecting 42.2%. Male sex was associated with IgE-sensitization to airborne allergens at all ages (overall OR: 1.68, 95% CI 1.46–1.94) while there was no statistically significant association between sex and sensitization to food allergens (overall OR: 1.10, 95% CI 0.93–1.32). Levels of allergen-specific IgE did not differ significantly between males and females for any of the tested foods or airborne allergens at any age, following adjustment for multiple comparisons. Conclusion IgE-sensitization to airborne allergens increases with age up to young adulthood, whereas sensitization to food allergens seems to level off. Male sex is strongly associated with IgE-sensitization to airborne allergens from early childhood up to young adulthood. In contrast, there is little evidence for associations between sex and IgE-sensitization to foods.

Published
2020
Full Text
View/download PDF

3. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option

Author

Leif Bjermer, Marit Westman, Mats Holmström, and Magnus C. Wickman

Subjects
Allergic rhinitis, Azelastine, Fluticasone, MP-AzeFlu, Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista®, Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.

Published
2019
Full Text
View/download PDF

4. Development of sensitization to peanut and storage proteins and relation to markers of airway and systemic inflammation: A 24‐year follow‐up

Author

Sandra G. Tedner, Susanna Klevebro, Anna Bergström, Inger Kull, Niklas Andersson, Magnus P. Borres, Natalia Ballardini, Marit Westman, Jon R. Konradsen, Marianne van Hage, Caroline Nilsson, Erik Melén, and Anna Asarnoj

Subjects
molecular allergology, Respiratory Medicine and Allergy, Immunology, peanut allergy, Immunology and Allergy, birth cohort, FENO, OLINK, sensitization, Lungmedicin och allergi
Abstract

Background Long-time data of peanut allergy over time is sparse. We aimed to study the longitudinal development of sensitization to peanut extract and storage protein allergen molecules and associations with asthma status, airway and systemic inflammation markers. Methods The Swedish birth cohort BAMSE followed 4089 participants with questionnaires, clinical investigations and blood sampling between 0 and 24 years. Information on (i) background factors at 2 months, (ii) peanut allergy symptoms and IgE data (ImmunoCAP) at 4, 8, 16, and 24 years, and (iii) IgE to storage proteins, lung function data including exhaled nitric oxide (FENO) as well as systemic inflammatory markers at 24 years of age were collected. Results The prevalence of peanut extract sensitization, defined as IgE ≥ 0.35 kUA/L, was 5.4%, 8.0%, 7.5%, and 6.2% at 4, 8, 16, and 24 years of age, respectively. Between 8 and 24 years of age, (33/1565) participants developed IgE-ab to peanut extract (median 1,4, range 0.7–2.6 kUA/L), and among those 85% were also sensitized to birch. Only six individuals developed sensitization to Ara h 2 (≥0.1 kUA/L) between 8 and 24 years of age, of whom three had an IgE-ab level between 0.1–0.12 kUA/L. Storage protein sensitization was associated with elevated FENO, blood eosinophils and type 2 inflammation-related systemic proteins. Conclusion Sensitization to peanut extract after 4 years of age is mainly induced by birch cross-sensitization and IgE to Ara h 2 rarely emerges after eight years of age. Storage protein sensitization is associated with respiratory and systemic inflammation.

Published
2022

5. General Stress Among Young Adults with Asthma During the COVID-19 Pandemic

Author

Sandra Ekström, Antonios Georgelis, Inger Kull, Catarina Almqvist, Ida Mogensen, Marit Westman, Erik Melén, and Anna Bergström

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Population, Perceived Stress Scale, Anxiety, Health concerns, Young Adult, Epidemiology, Health care, Humans, Immunology and Allergy, Medicine, Young adult, Child, education, Pandemics, Rhinitis, Asthma, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, education.field_of_study, SARS-CoV-2, business.industry, Percieved stress, COVID-19, SD, Standard Deviation, Odds ratio, medicine.disease, Rhinitis, Allergic, Cross-Sectional Studies, BMI, Body mass Index, COVID-19, Corona virus disease of 2019, Original Article, Birth Cohort, Female, medicine.symptom, business, PSS-10, perceived stress scale, Demography
Abstract

BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has profoundly affected the lives of the global population. OBJECTIVE To explore anxiety and stress in relation to COVID-19 among young adults, and the potential influence of asthma and allergic rhinitis. METHODS This cross-sectional study included 1644 participants from the population-based birth cohort BAMSE (Swedish abbreviation for Children, Allergy, Milieu, Stockholm, Epidemiology), participating in a follow-up at age 24 years and a COVID-19 follow-up conducted in August-November 2020 (mean age, 25.3 years). Anxiety and concern related to COVID-19 were analyzed as general anxiety, concern of own health and health of family members, and contact with online health care providers due to concern about COVID-19. Stress was measured with the perceived stress scale. RESULTS Around half the participants reported increased anxiety due to COVID-19, and this was more common among females (57.0%, compared with 42.6% in males; P < .001). Young adults with asthma reported more concern about their own health (adjusted odds ratio, 1.50; 95% CI, 1.12-2.02) and perceived stress (adjusted regression coefficient [adjusted β], 1.49; 95% CI, 0.52-2.45) compared with peers without asthma, and this was more pronounced among females and those with uncontrolled asthma. Symptoms of allergic rhinitis were not associated with increased concern or anxiety in relation to COVID-19. CONCLUSIONS Young adults with asthma experience more COVID-19-related health concerns, compared with those without asthma, especially females and participants with uncontrolled asthma This needs to be considered in the care of young people with asthma.

Published
2022

6. Food allergy and hypersensitivity reactions in children and adults—A review

Author

Sandra G. Tedner, Anna Asarnoj, Helena Thulin, Marit Westman, Jon R. Konradsen, and Caroline Nilsson

Subjects
Food, Child, Preschool, Internal Medicine, Animals, Humans, Eosinophilic Esophagitis, Allergens, Immunoglobulin E, Food Hypersensitivity
Abstract

Adverse reactions after food intake are commonly reported and a cause of concern and anxiety that can lead to a very strict diet. The severity of the reaction can vary depending on the type of food and mechanism, and it is not always easy to disentangle different hypersensitivity diagnoses, which sometimes can exist simultaneously. After a carefully taken medical history, hypersensitivity to food can often be ruled out or suspected. The most common type of allergic reaction is immunoglobulin E (IgE)-mediated food allergy (prevalence 5-10%). Symptoms vary from mild itching, stomach pain, and rash to severe anaphylaxis. The definition of IgE-mediated food allergy is allergic symptoms combined with specific IgE-antibodies, and therefore only IgE-antibodies to suspected allergens should be analyzed. Nowadays, methods of molecular allergology can help with the diagnostic process. The most common allergens are milk and egg in infants, peanut and tree nuts in children, and fish and shellfish in adults. In young children, milk/egg allergy has a good chance to remit, making it important to follow up and reintroduce the food when possible. Other diseases triggered by food are non-IgE-mediated food allergy, for example, eosinophilic esophagitis, celiac disease, food protein-induced enterocolitis syndrome, and hypersensitivity to milk and biogenic amines. Some of the food hypersensitivities dominate in childhood, others are more common in adults. Interesting studies are ongoing regarding the possibilities of treating food hypersensitivity, such as through oral immunotherapy. The purpose of this review was to provide an overview of the most common types of food hypersensitivity reactions.

Published
2021

7. High‐dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase

Author

Åslög Dahl, Dan Weinfeld, Marit Westman, Agneta Karlsson, Eric Hjalmarsson, Ulla Westin, Ola Winqvist, Susanna Kumlien Georén, Karin Lundkvist, Lars-Olaf Cardell, and Laila Hellkvist

Subjects
medicine.medical_specialty, medicine.medical_treatment, Immunology, Provocation test, Poaceae, Double-Blind Method, Quality of life, Internal medicine, medicine, Dose escalation, High doses, Humans, Immunologic Factors, Immunology and Allergy, Symptom control, Dosing, business.industry, Rhinitis, Allergic, Seasonal, Immunotherapy, Allergens, Rhinitis, Allergic, Treatment Outcome, Desensitization, Immunologic, Quality of Life, Pollen, Active treatment, business
Abstract

Background: The same dosing schedule, 1000 SQ-U times three, with one-month intervals, have been evaluated in most trials of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis (AR). The present studies evaluated if a dose escalation in ILIT can enhance the clinical and immunological effects, without compromising safety. Methods: Two randomized double-blind placebo-controlled trials of ILIT for grass pollen-induced AR were performed. The first included 29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients. An up-dosage of 1000–3000–10,000 (5000 + 5000 with 30 minutes apart) SQ-U with 1 month in between was evaluated. Results: Doses up to 10,000 SQ-U were safe after recent SCIT. The combined symptom-medication scores (CSMS) were reduced by 31% and the grass-specific IgG4 levels in blood were doubled. In ILIT de novo, the two first patients that received active treatment developed serious adverse reactions at 5000 SQ-U. A modified up-dosing schedule; 1000–3000–3000 SQ-U appeared to be safe but failed to improve the CSMS. Flow cytometry analyses showed increased activation of lymph node-derived dendritic but not T cells. Quality of life and nasal provocation response did not improve in any study. Conclusion: Intralymphatic immunotherapy in high doses after SCIT appears to further reduce grass pollen-induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3000 SQ-U should be avoided. (Less)

Published
2021

8. Alpha-gal sensitization among young adults is associated with male sex and polysensitization

Author

Natalia Ballardini, Magnus P. Borres, Danijela Apostolovic, Anna Asarnoj, Niklas Andersson, Anna Bergström, Erik Melén, M.B. Gea Kiewiet, Inger Kull, Marianne van Hage, and Marit Westman

Subjects
Male, business.industry, Respiratory Medicine and Allergy, Alpha (ethology), Allergens, Young Adult, medicine.anatomical_structure, Immunology, medicine, Immunology and Allergy, Humans, Young adult, business, Sensitization, Food Hypersensitivity, Lungmedicin och allergi
Published
2022

9. High dose pollen intralymphatic immunotherapy: two RDBPC trials question the benefit of dose increase

Author

Alsog Dahl, Ola Winquist, Eric Hjalmarsson, Dan Weinfeld, Lars-Olaf Cardell, Karin Lundkvist, Marit Westman, Susanna Kumlien Georén, Ulla Petersson Westin, Laila Hellkvist, and Agneta Karlsson

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Provocation test, Immunotherapy, medicine.disease_cause, medicine.anatomical_structure, Internal medicine, Pollen, Grass pollen, medicine, High doses, Active treatment, Dosing, business, Lymph node
Abstract

Background The same dosing schedule, 1000 SQ-U times three, with one-month intervals, have been evaluated in most trials of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis (AR). The present studies evaluated if a dose escalation in ILIT can enhance the clinical and immunological effects, without compromising safety. Methods Two randomized double-blind placebo-controlled trials of ILIT for grass pollen induced AR were performed. The first included 29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients. An up-dosage of 1000-3000-10 000 (5000 + 5000 with 30 minutes apart) SQ-U with one month in between was evaluated. Results Doses up to 10 000 SQ-U was safe after recent SCIT. The combined symptom-medication scores (CSMS) were reduced by 31% and the grass specific IgG4 levels in blood were doubled. In ILIT de novo, the two first patients that received active treatment developed serious adverse reactions at 5000 SQ-U. A modified up-dosing schedule; 1000-3000-3000 SQ-U appeared to be safe but failed to improve the CSMS. Flow cytometry analyses showed increased activation of lymph node derived dendritic but not T-cells. Quality of life and nasal provocation response did not improve in any study. Conclusion ILIT in high doses after SCIT appears to further reduce grass pollen induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3 000 SQ-U should be avoided.

Published
2021

10. Stathmin and EGFR correlates to HPV status and clinical outcome in sinonasal inverted papilloma

Author

Pär Stjärne, Anders Näsman, Linda Marklund, Lalle Hammarstedt-Nordenvall, Alexandra Elliot, and Marit Westman

Subjects
Inverted papilloma, Stathmin, macromolecular substances, law.invention, Malignant transformation, 03 medical and health sciences, 0302 clinical medicine, law, Sinonasal inverted papilloma, medicine, Humans, Epidermal growth factor receptor, 030223 otorhinolaryngology, Polymerase chain reaction, Papilloma, Inverted, biology, business.industry, Papillomavirus Infections, General Medicine, medicine.disease, ErbB Receptors, Otorhinolaryngology, Dysplasia, Cancer research, biology.protein, Immunohistochemistry, Neoplasm Recurrence, Local, business, Paranasal Sinus Neoplasms
Abstract

BACKGROUND Inverted papilloma (IP) is a locally destructive benign tumour of the sinonasal mucosa with a tendency for malignant transformation. Stathmin and epidermal growth factor receptor (EGFR) are important markers in cancer prognosis. Here we investigate if expression of stathmin and EGFR correlate to dysplasia, recurrence and HPV in IP. METHODS 98 patients with IP diagnosed 2000-2010 were analyzed for stathmin and EGFR by immunohistochemistry (IHC) and HPV by polymerase chain reaction assay (PCR). RESULTS All IPs expressed stathmin while its expression was absent or weak in normal mucosa. Dysplasia was present in 26,7% of IPs with high stathmin expression while only 7.4% of IPs with low stathmin expression showed dysplasia. Stathmin positive IPs showed a trend towards earlier recurrences. 57.1% of IP expressed EGFR but no significant association was seen between EGFR-positivity and recurrence or dysplasia. EGFR was expressed by 91.7% of the HPV-positive IPs compared to 52,3% of the HPV negative IPs. CONCLUSIONS EGFR expression is significantly higher in HPV positive IP. Stathmin is expressed by all IP tumour cells. Stathmin was also associated with dysplasia and a trend towards a correlation between stathmin positivity and recurrence was found. Stathmin and EGFR might therefore be considered therapeutic targets.

Published
2019

11. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis

Author

Linda Cox, Antoine Azar, G. Walter Canonica, Sandra Y. Lin, Wytske Fokkens, Peter S. Creticos, Rodney J. Schlosser, James W. Mims, Fuad M. Baroody, Adrienne M. Laury, Deborah Jarvis, Luke Rudmik, Adam S. DeConde, Charles S. Ebert, Cecelia Damask, Gianna Moscato, Timothy L. Smith, Maritta Kilpeläinen, Cristoforo Incorvaia, Russell A Settipane, Hemant Sharma, Ayesha N. Khalid, Thomas Chacko, Steven M. Houser, William R. Reisacher, Maria C Veling, Carrie E. Flanagan, Ashleigh A. Halderman, Erik Melén, Jan Gosepath, Jeremiah A. Alt, Amber U Luong, Peter H. Hwang, Matthew W. Ryan, Hans Jürgen Hoffman, Cemal Cingi, Helene J. Krouse, Carmen Rondon, Harold S. Nelson, Giorgio Ciprandi, Bradley F. Marple, Christine B. Franzese, Adnan Custovic, Sarah K. Wise, K. Christopher McMains, Mark A. Zacharek, Désirée Larenas-Linnemann, Oliver Pfaar, Jean Anderson Eloy, Joshua M. Levy, Elina Toskala, Pongsakorn Tantilipikorn, Monica O. Patadia, Jacquelynne P. Corey, Jens M. Hohlfeld, Aziz Sheikh, Joaquim Mullol, Cezmi A. Akdis, Claus Bachert, Jody R. Tversky, De Yun Wang, John M. DelGaudio, Richard R. Orlandi, Magnus Wickman, Joaquín Sastre, Edward D. McCoul, Michael P. Platt, Robert G. Hamilton, Marit Westman, Stella E. Lee, Todd T. Kingdom, and Ruby Pawankar

Subjects
Rhinology, Medical education, medicine.medical_specialty, Modalities, business.industry, MEDLINE, Evidence-based medicine, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), 030228 respiratory system, Otorhinolaryngology, Multidisciplinary approach, medicine, Immunology and Allergy, 030223 otorhinolaryngology, business, Strengths and weaknesses, Disease burden
Abstract

BACKGROUND: Critical examination of the quality and validity of available allergic rhinitis (AR) literature is necessary to improve understanding and to appropriately translate this knowledge to clinical care of the AR patient. To evaluate the existing AR literature, international multidisciplinary experts with an interest in AR have produced the International Consensus statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR). METHODS: Using previously described methodology, specific topics were developed relating to AR. Each topic was assigned a literature review, evidence-based review (EBR), or evidence-based review with recommendations (EBRR) format as dictated by available evidence and purpose within the ICAR:AR document. Following iterative reviews of each topic, the ICAR:AR document was synthesized and reviewed by all authors for consensus. RESULTS: The ICAR:AR document addresses over 100 individual topics related to AR, including diagnosis, pathophysiology, epidemiology, disease burden, risk factors for the development of AR, allergy testing modalities, treatment, and other conditions/comorbidities associated with AR. CONCLUSION: This critical review of the AR literature has identified several strengths; providers can be confident that treatment decisions are supported by rigorous studies. However, there are also substantial gaps in the AR literature. These knowledge gaps should be viewed as opportunities for improvement, as often the things that we teach and the medicine that we practice are not based on the best quality evidence. This document aims to highlight the strengths and weaknesses of the AR literature to identify areas for future AR research and improved understanding.

Published
2018

12. 国际过敏与鼻科学共识声明 : 变应性鼻炎

Author

Sarah K. Wise, Sandra Y. Lin, Elina Toskala, Richard R. Orlandi, Cezmi A. Akdis, Jeremiah A. Alt, Antoine Azar, Fuad M. Baroody, Claus Bachert, G. Walter Canonica, Thomas Chacko, Cemal Cingi, Giorgio Ciprandi, Jacquelynne Corey, Linda S. Cox, Peter Socrates Creticos, Adnan Custovic, Cecelia Damask, Adam DeConde, John M. DelGaudio, Charles S. Ebert, Jean Anderson Eloy, Carrie E. Flanagan, Wytske J. Fokkens, Christine Franzese, Jan Gosepath, Ashleigh Halderman, Robert G. Hamilton, Hans Jürgen Hoffman, Jens M. Hohlfeld, Steven M. Houser, Peter H. Hwang, Cristoforo Incorvaia, Deborah Jarvis, Ayesha N. Khalid, Maritta Kilpeläinen, Todd. T. Kingdom, Helene Krouse, Desiree Larenas‐Linnemann, Adrienne M. Laury, Stella E. Lee, Joshua M. Levy, Amber U. Luong, Bradley F. Marple, Edward D. McCoul, K. Christopher McMains, Erik Melén, James W. Mims, Gianna Moscato, Joaquim Mullol, Harold S. Nelson, Monica Patadia, Ruby Pawankar, Oliver Pfaar, Michael P. Platt, William Reisacher, Carmen Rondón, Luke Rudmik, Matthew Ryan, Joaquin Sastre, Rodney J. Schlosser, Russell A. Settipane, Hemant P. Sharma, Aziz Sheikh, Timothy L. Smith, Pongsakorn Tantilipikorn, Jody R. Tversky, Maria C. Veling, De Yun Wang, Marit Westman, Magnus Wickman, Mark Zacharek, Ear, Nose and Throat, and AII - Inflammatory diseases

Subjects
Otorhinolaryngology, 1107 Immunology, Immunology and Allergy
Published
2018

14. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly ( <scp>MACVIA</scp> ‐ <scp>ARIA</scp> ) ‐ <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site ( <scp>GARD</scp> research demonstration project)

Author

Alan Estrada-Cardona, Désirée Larenas-Linnemann, A. A. Cruz, A. Bedbrook, Torsten Zuberbier, B. De Martino, Esben Eller, K. C. Bergmann, A. Farsi, Ana Maria Carriazo, João Fonseca, Manuel Teixeira Veríssimo, Carsten Bindslev-Jensen, S. La Grutta, G. De Feo, Rimantas Stukas, M Doulapsi, Jean-Louis Pépin, Adnan Custovic, Gabrielle L. Onorato, Oliver Pfaar, U. Trama, Timo E. Strandberg, Ana Margarida Pereira, M. Bochenska Marciniak, V. Tibaldi, M. H. Garcia Cruz, Juan Carlos Ivancevich, Alessandro Vatrella, Denis Caillaud, Tuula Vasankari, J. A. Rizzo, Robyn E O'Hehir, Anne Lise Courbis, D. Lauri, Benoit Pugin, José Luis Gálvez-Romero, Juan José Matta-Campos, Jean Bousquet, G. De Vries, Johanna Salimäki, A. Yorgancioglu, A. Ciceran, C. Dario, Luc Colas, W. J. Fokkens, J. Millot-Keurinck, Josep M. Antó, I. Annesi-Maesano, F. Corti, Nick A. Guldemond, Renzo Angles, Arūnas Valiulis, Vicky Kritikos, Martin Wagenmann, J Mullol, G. Canfora, Peter Hellings, M. T. Ventura, Bilun Gemicioglu, Martín Bedolla-Barajas, Elísio Costa, M. Guidacci, Milan Sova, Isabelle Bosse, Jesús Guillermo Espinoza-Contreras, D. Conforti, J. Correia de Sousa, M. Sorlini, Massimo Triggiani, Jorge Maspero, Maciej Kupczyk, Rachel Tan, Jean-François Ferrero, D Caiazza, N. Di Carluccio, O. Kalayci, L. Lewis, Javier Gómez-Vera, Antoine Magnan, J. Farrell, T. Dedeu, I. Bogus-Buczynska, J. Just, Erkka Valovirta, Frederic Viart, Daniel Laune, Marco Nalin, Regina Roller-Wirnsberger, A. Szylling, Caterina Bucca, G. Castellano, Davide Caimmi, V. Stroetmann, Filip Raciborski, Rafael Stelmach, Luiana Hernández-Velázquez, Violeta Kvedariene, E. Bacci, Maurizio Romano, Cemal Cingi, A. C. Pozzi, Marit Westman, I. Young, S. Forti, M. T. Burguete Cabañas, Bolesław Samoliński, Ruta Dubakiene, E. Zernotti, A. Blua, Ioana Agache, B. A. Barreto, João O. Malva, J. Lavrut, Thomas Keil, Miguel Alejandro Medina-Ávalos, C. I. García-Cobas, Jorge A. Luna-Pech, J. F. Fontaine, R. Emuzyte, Biljana Cvetkovski, Ruth Murray, Giovanni Rolla, Antonella Muraro, Jussi Karjalainen, H. Neffen, E Cousein, Claus Bachert, V. Kolek, Magnus Wickman, Elaine Colgan, Mario R. Romano, Miguel A. Sierra, Erik Melén, A. Senn, Paulo Augusto Moreira Camargos, C. Cartier, Jawad Hajjam, Ali Fuat Kalyoncu, S. Shamai, Sinthia Bosnic-Anticevich, L. Cecci, Renaud Louis, Ana Todo-Bom, Rodolphe Bourret, Enrica Menditto, Nikolaos G. Papadopoulos, M. M. Ciaravolo, Emmanuel P. Prokopakis, G. Passalacqua, P. V. Tomazic, Edgardo Jares, C. Robalo-Cordeiro, L. Bertorello, M. Bewick, Roland Buonaiuto, A. Romano, Sîan A Williams, Anabela Mota-Pinto, Marcello Persico, Luigi Napoli, M. Lessa, Ralph Mösges, G. Levato, M. Nogues, Tari Haahtela, Edyta Krzych-Fałta, Janet Rimmer, F. de Blay, A. Zurkuhlen, Ludger Klimek, I. Baroni, Niels H. Chavannes, Faradiba Sarquis Serpa, T. Bieber, E. Asayag, Yves Dauvilliers, Piotr Lacwik, R. M. Cortés-Grimaldo, Piotr Kuna, Cristiana Stellato, A Valero, J. da Silva, M. Illario, S Birov, R. Gerth van Wijk, M. R. Aliberti, Inger Kull, Z. Gutter, Sanna Toppila-Salmi, Gérard Dray, Sylvie Arnavielhe, Victoria Cardona, M. Morais-Almeida, Guy Joos, S. Di Capua Ercolano, J. Coll, M. van Eerd, C. Wanscher, N. Khaltaev, Agnieszka Lipiec, Mónica Rodríguez-González, Oscar Mayora, Pascal Demoly, G. Moda, S. Palkonen, I. Lieten, and B. De Oliviera

Subjects
Gerontology, Allergy, Carat, medicine.medical_specialty, Visual analogue scale, business.industry, Immunology, Alternative medicine, medicine.disease, Comorbidity, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), 030228 respiratory system, medicine, Physical therapy, Immunology and Allergy, Multimorbidity, 030212 general & internal medicine, business, health care economics and organizations, Asthma
Abstract

The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives whilst ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study was to transfer innovation from an app developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve the understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will be: (i) to assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) to study the phenotypic characteristics and treatment over a 1-year period of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) to follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults.

Published
2017

15. Human papillomavirus and infiltration of CD8- and Foxp3-positive immune cells in sinonasal inverted papillomas

Author

Anders Näsman, Lalle Hammarstedt-Nordenvall, Marit Westman, Pär Stjärne, Alexandra Elliot, and Linda Marklund

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Adolescent, Inverted papilloma, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Benign tumor, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Immune system, Medicine, Humans, Human papillomavirus, 030223 otorhinolaryngology, Papillomaviridae, Cyclin-Dependent Kinase Inhibitor p16, Aged, Retrospective Studies, Aged, 80 and over, Sweden, Papilloma, Inverted, business.industry, virus diseases, FOXP3, General Medicine, Middle Aged, medicine.disease, Otorhinolaryngology, Dysplasia, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Infiltration (medical), CD8, Biomarkers, Paranasal Sinus Neoplasms
Abstract

Background: Sinonasal inverted papilloma (IP) is a benign tumor with a high risk of local recurrence and a potential to malignify and Human papillomavirus (HPV) has been suggested an etiological fa...

Published
2019

16. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option

Author

Marit Westman, Magnus Wickman, Leif Bjermer, and Mats Holmström

Subjects
lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Context (language use), Review, Disease, Allergic rhinitis, Fluticasone propionate, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), MP-AzeFlu, medicine, media_common.cataloged_instance, European union, 030223 otorhinolaryngology, Intensive care medicine, Asthma, Fluticasone, media_common, Azelastine, business.industry, General Medicine, medicine.disease, 030228 respiratory system, lcsh:RC581-607, business, medicine.drug
Abstract

Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista®, Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.

Published
2019

17. Paving the way of systems biology and precision medicine in allergic diseases: the Me <scp>DALL</scp> success story

Author

Erik Melén, Rudolph Valenta, Fanny Rancière, C. Tischer, I. Skrindo, Hamida Hammad, V. Anastasova, Leda Chatzi, C. Hohman, Magnus Wickman, M P Fantini, M. Torrent, Pascal Demoly, S. Palkonen, Esben Eller, Carsten Bindslev-Jensen, N. Anderson, A. Bedbrook, Torsten Zuberbier, Rachel Nadif, Francesco Forastiere, K. Wenger, Sybille Koletzko, I. Annesi-Maesano, Jonathan M. Coquet, Yvan Saeys, Joachim Heinrich, Steffen Lau, Marit Westman, Bénédicte Jacquemin, L. von Hertzen, M. Standl, Marta Benet, Martijn J. Schuijs, Mirela Curin, Dirkje S. Postma, Valérie Siroux, Bart N. Lambrecht, E. Minina, Christian Lupinek, Vegard Hovland, Irina Lehmann, Jordi Sunyer, Dieter Maier, Stephane Ballereau, Anna Asarnoj, Jean Bousquet, Isabelle Momas, A. Rial-Sebbag, Gerard H. Koppelman, Cezmi A. Akdis, Isabelle Pin, A. von Berg, Henriette A. Smit, Manolis Kogevinas, Beatrix Gerhard, Claus Bachert, Emilie Burte, S. Guerra, Sandra Wieser, Bert Brunekreef, Johann Pellet, Ulrike Gehring, Renata Kiss, Petter Mowinckel, Cheng-Jian Xu, Anne Cambon-Thomsen, Jordi Mestres, Theresa Keller, Martijn C. Nawijn, Ferran Ballester, N. Ballardini, Tari Haahtela, Mariona Pinart, Charles Auffray, J. Garcia-Aymerich, J. Just, R. Albang, Marek L. Kowalski, Marjan Kerkhof, Inger Kull, Mika J. Mäkelä, G. De Carlo, J. De Vocht, Kai-Håkon Carlsen, Sam Oddie, A. Arno, Rosemary R. C. McEachan, X. Basagana, Thomas Keil, Daniela Porta, M. Akdis, Anna Bergström, Nathanaël Lemonnier, Raphaëlle Varraso, John Wright, Josep M. Antó, K. C. Lødrup Carlsen, and D. Smagghe

Subjects
0301 basic medicine, Allergy, education.field_of_study, business.industry, Systems biology, Immunology, Population, Atopic dermatitis, Omics, medicine.disease, Precision medicine, 3. Good health, Review article, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030228 respiratory system, Immunology and Allergy, Medicine, media_common.cataloged_instance, European union, business, education, media_common
Abstract

MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015) has proposed an innovative approach to develop early indicators for the prediction, diagnosis, prevention and targets for therapy. MeDALL has linked epidemiological, clinical and basic research using a stepwise, large-scale and integrative approach: MeDALL data of precisely phenotyped children followed in 14 birth cohorts spread across Europe were combined with systems biology (omics, IgE measurement using microarrays) and environmental data. Multimorbidity in the same child is more common than expected by chance alone, suggesting that these diseases share causal mechanisms irrespective of IgE sensitization. IgE sensitization should be considered differently in monosensitized and polysensitized individuals. Allergic multimorbidities and IgE polysensitization are often associated with the persistence or severity of allergic diseases. Environmental exposures are relevant for the development of allergy-related diseases. To complement the population-based studies in children, MeDALL included mechanistic experimental animal studies and in vitro studies in humans. The integration of multimorbidities and polysensitization has resulted in a new classification framework of allergic diseases that could help to improve the understanding of genetic and epigenetic mechanisms of allergy as well as to better manage allergic diseases. Ethics and gender were considered. MeDALL has deployed translational activities within the EU agenda.

Published
2016

18. Type 2 Inflammatory Shift in Chronic Rhinosinusitis During 2007–2018 in Belgium.

Author

Karin, Jonstam, Tim, Delemarre, Gabriele, Holtappels, Cardell, Lars‐Olaf, Marit, Westman, and Claus, Bachert

Abstract

Objectives/Hypothesis: Chronic rhinosinusitis (CRS) is a heterogenic disease with different inflammatory patterns depending on the presence (CRSwNP) or absence (CRSsNP) of polyps and geographical location. A shift toward type 2 endotype has been seen in Asia. We aim to investigate whether there has been type 2 shift in Belgium and to further endotype CRS based on clinical markers. Study design: Prospective descriptive study. Methods: Four hundred and thirty eight patients with CRS undergoing sinus surgery at Ghent University Hospital between 2007 and 2018 were included and stratified based on phenotype, comorbidities, inflammatory markers in tissue, and two different time points of surgery. Tissue samples from surgery were analyzed for type 2 markers. In a subgroup of CRSwNP blood eosinophils (EBC) was available. Results: There was an increase in type 2 inflammatory markers in the latter group versus the earlier, in non‐asthmatic, non‐allergic CRS patients regardless of phenotype. The proportion of IL‐5+ patients was elevated in the latter group in CRSwNP. Inflammatory markers and comorbidities differ between IL‐5+ CRSsNP and CRSwNP subjects, no difference was seen in IL‐5− CRS. EBC can together with information on comorbidities help identify type 2 CRSwNP in a clinical setting. Conclusion: There is a shift toward type 2 inflammation within the CRS population over recent 8 years also in Belgium. This shift implies that we expect to see more cases of severe and difficult to treat CRS in the future. Polyp formation is not directly linked to the presence or concentrations of type 2 inflammatory markers. Clinical parameters and EBC > 300 cells/μL can be used to identify type 2 CRSwNP. Level of Evidence: 3. Laryngoscope, 131:E1408–E1414, 2021 [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

19. Sensitization to grass pollen allergen molecules in a birth cohort—natural Phl p 4 as an early indicator of grass pollen allergy

Author

Pia Gattinger, Danijela Apostolovic, Erik Melén, Jean Bousquet, Niklas Andersson, Anna Bergström, Irene Mittermann, Karin Åberg, Marianne van Hage, Magnus Wickman, Marit Westman, Josep M. Antó, Rudolf Valenta, Christian Lupinek, Division of Infectious Diseases [Stockholm, Sweden] (Department of Medicine Solna), Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Medizinische Universität Wien = Medical University of Vienna, The Institute of Environmental Medicine [Stockholm] (IMM), Sachs' Children's Hospital, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, IMIM-Hospital del Mar, Generalitat de Catalunya, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Federal Medical-Biological Agency of Russia, Sechenov First Moscow State Medical University, and Salvy-Córdoba, Nathalie

Subjects
0301 basic medicine, Allergy, Microarray, Immunoglobulin E, medicine.disease_cause, Allergic rhinitis, MESH: Immunologic, Tests, Phleum, Plant Extracts / immunology, Plant Proteins / immunology, Pollen / immunology, Prevalence, Prognosis, Cohort Studies, 0302 clinical medicine, Allergen, Surveys and Questionnaires, MeDALL, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Child, Sensitization, Plant Proteins, 2. Zero hunger, Timothy-grass, education.field_of_study, biology, Cohort, Grass pollen, food and beverages, medicine.anatomical_structure, Child, Preschool, Pollen, IgE, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, Allergen molecules, Adolescent, Immunology, Population, MESH: Adolescent, Allergens / immunology, Humans, Immunization, Immunoglobulin E / metabolism, Immunologic Tests, 03 medical and health sciences, otorhinolaryngologic diseases, medicine, education, Skin Tests, Sweden, Plant Extracts, business.industry, MESH: Rhinitis, Allergic / diagnosis, Rhinitis, Allergic / epidemiology, Rhinitis, Allergic / immunology, Sweden / epidemiology, Allergens, biology.organism_classification, medicine.disease, Rhinitis, Allergic, Phl p 4, 030104 developmental biology, 030228 respiratory system, biology.protein, BAMSE, business
Abstract

International audience; Background: Grass pollen allergy is one of the most common allergies worldwide.Objective: The aim of this study was to evaluate the usefulness of grass pollen allergen molecules for prediction of grass pollen allergy during childhood and up to adolescence.Method: Questionnaire data and sera obtained from the study subjects at the ages of 4, 8, and 16 years from the population-based Barn/Children Allergy Milieu Stockholm Epidemiology birth cohort were used. Sera from 763 representative subjects with serum samples available at all 3 ages were analyzed for IgE reactivity to 8 Phleum pratense (Phl p) allergens (MeDALL [Mechanisms for the Development of Allergies] chip) and to timothy grass extract (ImmunoCAP). Allergic rhinitis to grass pollen (ARg) was defined as upper airway symptoms during grass pollen exposure.Results: The prevalence of sensitization to any Phl p molecule was higher compared with that to timothy extract at all 3 ages: at the age of 4 years, 9.7% versus 6.8%; at the age of 8 years, 28.4% versus 15.3%; and at the age of 16 years, 37.1% versus 27.1%. General estimating equations analyses revealed that among children sensitized at the age of 4 years, the overall odds ratio (OR) of later ARg (up to 16 years) was increased only for IgE reactivity to Phl p 1 (OR = 4.9) and natural Phl p 4 (OR = 6.9). The likelihood of later symptoms increased with the number of allergen molecules; at the age of 4 years, 2 or more molecules predicted ARg to 78% and 3 or more molecules predicted ARg to 95%. A positive test result for timothy extract predicted ARg to 70%.Conclusions: Natural Phl p 4 is a hitherto unrecognized early indicator of grass pollen allergy, in addition to Phl p 1. To identify grass pollen sensitization and predict later ARg, allergen molecules are of added value to timothy extract alone and may help clinicians improve prediction of grass pollen allergy.

Published
2020

20. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study

Author

Ralph Mösges, T. Keil, Davide Caimmi, N. Ballardini, Thomas B. Casale, M. Morais Almeida, M. Rodriguez Gonzalez, Massimo Triggiani, Erik Melén, M. Wickman, Filip Raciborski, Sinthia Bosnic-Anticevich, P. V. Tomazic, Rafael Stelmach, Pascal Demoly, W. J. Fokkens, A. Bedbrook, Maciej Kupczyk, Jean Bousquet, K. C. Bergmann, A. Valero, M. T. Burguete Cabañas, Valérie Siroux, I. Annesi-Maesano, Torsten Zuberbier, Sanna Toppila-Salmi, Juan Carlos Ivancevich, A. Valiulis, Olivier Vandenplas, Ioana Agache, Frederic Viart, F. Portejoie, Cristiana Stellato, Josep M. Antó, D. Laune, V. Kvedariene, D. Larenas-Linnemann, J. da Silva, Ruth Murray, Piotr Kuna, Esben Eller, F. Sarquis-Serpa, Isabelle Bosse, Claus Bachert, P. Devillier, R. Bourret, M. L. Kowalski, Bilun Gemicioglu, Erkka Valovirta, Alvaro A. Cruz, M. Bewick, Tari Haahtela, O. Spranger, A. Yorgancioglu, Enrica Menditto, Aziz Sheikh, G. De Vries, Marit Westman, Oliver Pfaar, S. Arnavielhe, C. Cartier, G. Passalacqua, Dermot Ryan, S. Shamai, B. Samolinski, A. Todo Bom, Martin Sørensen, Inger Kull, M. van Eerd, Carsten Bindslev-Jensen, Niels H. Chavannes, Joaquim Mullol, T. Bieber, João Fonseca, G. Vezzani, Robyn E O'Hehir, Peter Hellings, M. T. Ventura, L. Klimek, J. Just, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], University of Helsinki, 'Federico II' University of Naples Medical School, Département Chirurgie Pédiatrique [CHRU Montpellier], Pôle Femme Mère Enfant [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Heidelberg University, University of Barcelona, Karl-Franzens-Universität [Graz, Autriche], University of Turku, Vilnius University [Vilnius], University of Edinburgh, Ghent University Hospital, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], The University of Sydney, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J., Devillier, P., Anto, J. M., Bewick, M., Haahtela, T., Arnavielhe, S., Bedbrook, A., Murray, R., van Eerd, M., Fonseca, J. A., Morais Almeida, M., Todo Bom, A., Menditto, E., Passalacqua, G., Stellato, C., Triggiani, M., Ventura, M. T., Vezzani, G., Annesi-Maesano, I., Bourret, R., Bosse, I., Caimmi, D., Cartier, C., Demoly, P., Just, J., Portejoie, F., Siroux, V., Viart, F., Bergmann, K. C., Keil, T., Klimek, L., Mosges, R., Pfaar, O., Shamai, S., Zuberbier, T., Mullol, J., Valero, A., Spranger, O., Tomazic, P. V., Kowalski, M. L., Kuna, P., Kupczyk, M., Raciborski, F., Samolinski, B., Toppila-Salmi, S. K., Valovirta, E., Cruz, A. A., Sarquis-Serpa, F., da Silva, J., Stelmach, R., Larenas-Linnemann, D., Rodriguez Gonzalez, M., Burguete Cabanas, M. T., Kvedariene, V., Valiulis, A., Chavannes, N. H., Fokkens, W. J., Ryan, D., Sheikh, A., Bachert, C., Hellings, P. W., Vandenplas, O., Ballardini, N., Kull, I., Melen, E., Westman, M., Wickman, M., Bindslev-Jensen, C., Eller, E., Bosnic-Anticevich, S., O'Hehir, R. E., Agache, I., Bieber, T., Casale, T., Gemicioglu, B., Ivancevich, J. C., De Vries, G., Sorensen, M., Yorgancioglu, A., and Laune, D.

Subjects
Male, Allergy, SYMPTOMS, IMPACT, CHILDREN, WORLD-HEALTH-ORGANIZATION, Review, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, QUALITY-OF-LIFE, conjunctiviti, Prevalence, conjunctivitis, Immunology and Allergy, Prospective Studies, Young adult, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Child, Prospective cohort study, asthma, multimorbidit, rhinitis, work productivity, Nose, Aged, 80 and over, Respiratory organs diseases, Middle Aged, Mobile Applications, 3. Good health, rhiniti, medicine.anatomical_structure, Research Design, MEDALL, GA(2)LEN, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Adolescent, multimorbidity, Visual analogue scale, Mobile Application, Immunology, MECHANISMS, Malalties de l'aparell respiratori, Young Adult, 03 medical and health sciences, Internal medicine, Hypersensitivity, medicine, Journal Article, Humans, asthma, conjunctivitis, multimorbidity, rhinitis, work productivity, Aged, Asthma, Science & Technology, business.industry, medicine.disease, Patient Outcome Assessment, Prospective Studie, Morbiditat, 030228 respiratory system, Observational study, Rhinithis, VISUAL ANALOG SCALE, Morbidity, business
Abstract

BACKGROUND: Multimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary. METHODS: We undertook a 1-year prospective observational study in which 4 210 users and 32 585 days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels

Published
2018

21. Impact of IgE sensitization and rhinitis on inflammatory biomarkers and lung function in adolescents with and without asthma

Author

Erik Melén, Marit Westman, Marianne van Hage, Anna Bergström, Natalia Ballardini, Inger Kull, Gunnar Lilja, Catarina Almqvist, and Jenny Hallberg

Subjects
0301 basic medicine, Spirometry, Male, medicine.medical_specialty, Adolescent, Immunology, Immunoglobulin E, Gastroenterology, Cohort Studies, 03 medical and health sciences, FEV1/FVC ratio, 0302 clinical medicine, Internal medicine, Oscillometry, medicine, Immunology and Allergy, Humans, Longitudinal Studies, Lung, Lung function, Sensitization, Asthma, Rhinitis, Sweden, biology, medicine.diagnostic_test, business.industry, respiratory system, medicine.disease, Inflammatory biomarkers, respiratory tract diseases, Eosinophils, 030104 developmental biology, medicine.anatomical_structure, 030228 respiratory system, Pediatrics, Perinatology and Child Health, biology.protein, Female, Immunization, business, Airway, Biomarkers
Abstract

BACKGROUND Both allergic and non-allergic rhinitis are associated with worse asthma control. However, it is unclear how IgE sensitization and/or rhinitis are associated with lung function. We therefore evaluated the effect of rhinitis and sensitization on lung function, including the periphery of the airway system, and inflammatory biomarkers in individuals with and without asthma. METHODS Participants in the BAMSE longitudinal birth cohort study underwent measures of spirometry, impulse oscillometry, and FeNO at age 16 years. Questionnaires were used to obtain data on asthma and rhinitis. Blood samples were analyzed for eosinophils and allergen-specific IgE. RESULTS Groups based on the combination of asthma, rhinitis, and sensitization were compared to a healthy reference group. Lower FEV1 /FVC levels were seen for groups with asthma only (adjusted mean difference -2.8% units (95% CI -4.7; -1.0), P

Published
2018

22. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author

Karin C. Lødrup Carlsen, L. Cecchi, F. Portejoie, T. Vontetsianos, Olivier Vandenplas, M. van Hague, D. Mora Bogado, M. Illario, Dana Wallace, L. Namazova-Baranova, E. Asayag, I. Ribeirinho, E. Costa, Shona Pedersen, Inger Kull, Davor Plavec, M. Morais-Almeida, Mickael Bewick, N.H. Chavannes, I. J. Ansotegui, G. De Carlo, K. S. Bennoor, Faradiba Sarquis Serpa, S. Arnavielle, F. Corti, Moises A. Calderon, Martín Bedolla-Barajas, Mette Sørensen, Isabella Annesi-Maesano, Elaine Colgan, Przemyslaw Kardas, M. van Eerd, Jorge Maspero, Valérie Siroux, Isabelle Momas, Ralph Mösges, Yves Dauvilliers, T. Keil, T. Bieber, Marit Westman, Rachel Nadif, O. Pfaar, A.C. Carvalho Coehlo, R. M. Cortés-Grimaldo, I. Skrindo, Piotr Kuna, Nicola Scichilone, Antonella Muraro, Kimihiro Okubo, Paulo Augusto Moreira Camargos, C. Cartier, Oliver Pfaar, K. Ohta, Barbara P. Yawn, Igor Kaidashev, Michel Thibaudon, X. Basagana, I. Kaidashev, Bilun Gemicioglu, S. Genova, Hae-Sim Park, J.J. Matta Campos, Simon Walker, Ulf Darsow, Fulvio Braido, J. Salimäki, T. Zuberbier, Raphaël Chiron, Mohammad Reza Masjedi, G.D. Marshall, Branislava Milenkovic, W. J. Fokkens, Eric D. Bateman, Robert M. Naclerio, Steve Montefort, M. de Fátima Emerson, T. Werfel, Cemal Cingi, A. Szylling, Martin Wagenmann, I. Baiardini, L. T. T. Le, N. Khaltaev, Ki-Suck Jung, Agnieszka Lipiec, Panayiotis K. Yiallouros, A Valero, R. Gerth van Wijk, L. Hernández, Marek L. Kowalski, C. Zubrinich, Sinthia Bosnic-Anticevich, Miguel A. Sierra, Erik Melén, T. Haahtela, Rute Almeida, Violeta Kvedariene, R. Pawankar, T.A. Popov, Flore Amat, Sanna Toppila-Salmi, M. Gotua, A. Sheikh, A. Bedbrook, Torsten Zuberbier, B. De Martino, Gérard Dray, Francesca Avolio, E. Mandajieva, B. Samolinski, Petr Panzner, P. Kuna, Philippe-Jean Bousquet, T. D. Nyembue, Luo Zhang, Leyla Namazova-Baranova, Ana Maria Carriazo, João Fonseca, E. Van Ganse, Roland Buhl, M. Bochenska Marciniak, Cristiana Stellato, J. da Silva, J. E. Gereda, Han-Jung Park, M.C. Costa-Dominguez, W. Carr, Dirceu Solé, S. Forti, Nanshan Zhong, Jordi Sunyer, Alain Didier, Y. Z. Chen, Thomas B. Casale, Jim Phillips, Isabelle Bosse, Manuel Teixeira Veríssimo, D. Y. Wang, U. Trama, Cristina Bárbara, David Somekh, T. Camuzat, R. N. Naclerio, Enrico Novellino, Leszek Klimek, M. Rodriguez Gonzalez, Holger J. Schünemann, Mario Barbagallo, D. Larenas-Linnemann, Mario Sánchez-Borges, Massimo Triggiani, Y. Okamoto, E. Mathieu-Dupas, N. Di Carluccio, S. Toppila-Salmi, Omer Kalayci, Rudolf Valenta, J. Coll, F. de Blay, Wienczyslawa Czarlewski, W. Pohl, Piotr Wroczyński, Kian Fan Chung, Nikolaos G. Papadopoulos, Pascal Demoly, Hubert Blain, M. Crescenzo, O. Kalayci, Leocadio Rodríguez-Mañas, G. Moda, L. Cox, Z. Gutter, A. Mair, Andrew Bush, Maria-Dolores Mogica-Martinez, Giorgio Walter Canonica, Antonio Valero, Daniel Laune, A. Zurkuhlen, Paul C. Potter, D. Wallace, Gabrielle L. Onorato, Mihaela Zidarn, E.P. Prokopakis, Anne Lise Courbis, Sergio Bonini, Ruta Dubakiene, A. Papi, Y. El-Gamal, Jacques Mercier, Wytske Fokkens, Rodolphe Bourret, S. Palkonen, A. Yorgancioglu, G. Vezzani, J. A. Rizzo, D. Plavec, D. Caillot, G. De Feo, E. Menditto, Caterina Bucca, A. C. Pozzi, Hironori Sagara, I. Grisle, I. Pin, Christopher E. Brightling, Ludger Klimek, F.F. Morato-Castro, Désirée Larenas-Linnemann, Alessandro Vatrella, A. A. Cruz, Guy Joos, E.D. Bateman, Erendira Rodriguez-Zagal, H. Douagui, T. To, Edgardo Jares, C. Bindslev-Jensen, G. Levato, J. O. B. Hourihane, R. Rajabian-Soderlund, C. Odzhakova, J. Bousquet, M. T. Ventura, Arzu Yorgancioglu, Osman M. Yusuf, H. J. Zar, Giovanni Rolla, Sebastian L. Johnston, M.S. Dykewicz, Esben Eller, A. Gamkrelidze, Filip Raciborski, Renzo Angles, Rafael Stelmach, M. Nogues, David Price, Mário Morais-Almeida, Tari Haahtela, Teresa To, D. Conforti, Stephen R. Durham, S. Gonzalez Diaz, V. Cardona, Werner Aberer, B. Milenkovic, Luigi Napoli, K. C. Bergmann, P W Hellings, M. Lessa, P. Panzner, Alfonso M. Cepeda Sarabia, M. Guidacci, A.L. Matos, Todor A. Popov, C. Suppli Ulrik, Diana Deleanu, N. de Paula Motta Rubini, Carsten Bindslev-Jensen, I. Majer, Ioana Agache, B. A. Barreto, R. Picard, Erkka Valovirta, A. Fink-Wagner, L. Colas, João O. Malva, Thomas Keil, M. T. Burguete Cabañas, Bolesław Samoliński, M.H. Garcia-Cruz, L.P. Boulet, K. Nekam, Edyta Krzych-Fałta, P. Devillier, J. Ferreira de Mello, Jussi Karjalainen, I. Bogus-Buczynska, Susan Waserman, Marcus Maurer, Tomas Chivato, Elena Bacci, M. Przemecka, Olga Lourenço, José Miguel Fuentes-Pérez, M. Zidarn, Talant Sooronbaev, J.M. Anto, W. Czarlewski, R. Murray, Luís Nogueira-Silva, G. Passalacqua, E. Chkhartishvili, Oscar Mayora, Victoria Cardona, M. Sondermann, Piotr Lacwik, S. Ouedraogo, I. Baroni, Artur Z. Białoszewski, G Scadding, J. Strozek, R. Emuzyte, Neven Miculinic, Ruby Pawankar, Ken Ohta, I. Agache, J.L. Gálvez-Romero, Nikos G. Papadopoulos, E. O. Meltzer, I. Annesi-Maesano, E. De Manuel Keenoy, Jorge A. Luna-Pech, Ana Margarida Pereira, Paul Potter, M. Ortega Cisneros, J. Li, K. F. Rabe, M. Rottem, Mikael Benson, Ali Fuat Kalyoncu, Dermot Ryan, Dieter Maier, C.Y. García-Cobas, S. Bialek, G. Du Toit, S. Shamai, S. Mavale-Manuel, Rojin Rajabian-Soderlund, Maddalena Illario, Philippe Devillier, F. Rodenas, Emmanuel P. Prokopakis, De Yun Wang, Niels H. Chavannes, E.H.D. Bel, Bianca Beghe, Sietze Reitsma, John Wright, O. Lourenço, L.T.T. Le, Josep M. Antó, T. Casale, Paul K. Keith, K. C. Lødrup Carlsen, P. Demoly, Mikael Kuitunen, Marc Humbert, A. M. Cepeda Sarabia, Ignacio J. Ansotegui, M.C. Rizzo, Davide Caimmi, Milan Sova, Nick A. Guldemond, P. Yakovliev, Judah A. Denburg, Jaime Correia de Sousa, Elisabete Melo-Gomes, Aziz Sheikh, I. Bosse, M. M. Ciaravolo, S. Di Capua Ercolano, Alpana Mair, P. Lieberman, Isabella Pali-Schöll, Leif Bjermer, G. De Vries, M. Roman Rodriguez, Johanna Salimäki, Carmen Panaitescu, F. Mihaltan, Giulia De Feo, F. E. R. Simons, A. Blua, B. Mahboub, D. Ryan, M. Bewick, Anabela Mota-Pinto, J.A. Fonseca, Neil Wilson, Marek Jutel, Dennis M. Williams, M. Akdis, Menachem Rottem, Marcello Persico, J. C. Ivancevich, Nelson Rosario, A. Farsi, Alvaro A. Cruz, Liguo Zhang, Anna Bedbrook, L. Bertorello, Magnus Wickman, Marilyn Urrutia-Pereira, O. Spranger, René Maximiliano Gómez, C. Bachert, Renaud Louis, Musa Khaitov, C. Stellato, Constantinos Pitsios, Roland Buonaiuto, A. Romano, Sîan A Williams, R. Puy, Daniela Rivero-Yeverino, Y. Mohammad, J. Farrell, Jan Brozek, Ricardo Pio Monti, E. Paulino, J. Correia de Sousa, Miguel Alejandro Medina-Ávalos, Jocelyne Just, Peter Valentin Tomazic, Jean-François Ferrero, Antoine Magnan, S. Waserman, J Rosado-Pinto, Maciek Kupczyk, C.S. Bosnic-Anticevich, T. Dedeu, Tommi Vasankari, R. Mösges, Robin O'Hehir, Ema Paulino, Peter Hellings, A. Neou, M. Wickman, D. Lauri, Jean Bousquet, A. Ciceran, Jacques Bouchard, Yehia El-Gamal, M.G. Dominguez-Silva, M.R. Alberti, Jean-Louis Pépin, Kimi Okubo, Juan Carlos Ivancevich, Patrik Eklund, Benoit Pugin, C. Dario, Mussa Khaitov, Luisa Brussino, A.G. Chuchalin, Elísio Costa, Susanna Palkonen, Lars Münter, Pedro Carreiro-Martins, R.E. Pulido Ross, Ettore Novellino, Kai-Håkon Carlsen, María Antonieta Guzmán, G.W. Canonica, Gabriel Onorato, Giuseppe De Carlo, R.E. Roller-Wirnsberger, Brian J. Lipworth, M. A. Guzman, J.N. Tebyriçá, Adnan Custovic, Yoshitaka Okamoto, Rimantas Stukas, P. Manning, J. Sastre-Dominguez, Caroline L.S. George, Robyn E O'Hehir, K. Maciej, Bassam Mahboub, J. F. Fontaine, Arũnas Valiulis, Xavier Rodó, D. Vicheva, G. Canfora, Vitalis Briedis, S. Rodrigues Valle, Mark S. Dykewicz, Joanne Rimmer, G. Castellano, B. Pigearias, A. L. Boner, Yunuen Rocío Huerta-Villalobos, Christine Rolland, H. Neffen, H. Arshad, Javier Gómez-Vera, P. Moura Santo, Frederic Viart, F. Blasi, J. Garcia-Aymerich, Lorenzo Cecchi, V. Niedeberger, Giorgio Ciprandi, F. Caballero-Fonseca, Jean-François Fontaine, J Mullol, Maurizio Romano, M. Viegi, Mario E. Zernotti, Arunas Valiulis, Anna Asarnoj, Antonio Nieto, J. Lavrut, D. Dokic, V. Kvedariene, Ewa Jassem, Cezmi A. Akdis, Ruth Murray, Claus Bachert, Peter Schmid-Grendelmeier, Emilie Burte, Joaquim Mullol, Guido Iaccarino, J. Kleine-Tebbe, P. V. Tomazic, E. Eller, Alessandro Fiocchi, H.J. Schunemann, M. Sorlini, C. Robalo-Cordeiro, Ana-Maria Todo-Bom, J. Brozek, Marco Nalin, Matteo Bonini, J. C. Sisul, S.E. Dahlen, F. Amat, Juan Carlos Sisul, Jawad Hajjam, Ana Todo-Bom, Enrica Menditto, Bousquet J., Hellings P.W., Agache I., Amat F., Annesi-Maesano I., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bedbrook A., Bennoor K., Bewick M., Bindslev-Jensen C., Bosnic-Anticevich S., Bosse I., Brozek J., Brussino L., Canonica G.W., Cardona V., Casale T., Cepeda Sarabia A.M., Chavannes N.H., Cecchi L., Correia de Sousa J., Costa E., Cruz A.A., Czarlewski W., De Carlo G., De Feo G., Demoly P., Devillier P., Dykewicz M.S., El-Gamal Y., Eller E.E., Fonseca J.A., Fontaine J.-F., Fokkens W.J., Guzman M.-A., Haahtela T., Illario M., Ivancevich J.-C., Just J., Kaidashev I., Khaitov M., Kalayci O., Keil T., Klimek L., Kowalski M.L., Kuna P., Kvedariene V., Larenas-Linnemann D., Laune D., Le L.T.T., Carlsen K.L., Lourenco O., Mahboub B., Mair A., Menditto E., Milenkovic B., Morais-Almeida M., Mosges R., Mullol J., Murray R., Naclerio R., Namazova-Baranova L., Novellino E., O'Hehir R.E., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Palkonen S., Panzner P., Papadopoulos N.G., Park H.-S., Paulino E., Pawankar R., Pfaar O., Plavec D., Popov T.A., Potter P., Prokopakis E.P., Rottem M., Ryan D., Salimaki J., Samolinski B., Sanchez-Borges M., Schunemann H.J., Sheikh A., Sisul J.-C., Rajabian-Soderlund R., Sooronbaev T., Stellato C., To T., Todo-Bom A.-M., Tomazic P.-V., Toppila-Salmi S., Valero A., Valiulis A., Valovirta E., Ventura M.-T., Wagenmann M., Wang D.Y., Wallace D., Waserman S., Wickman M., Yorgancioglu A., Zhang L., Zhong N., Zidarn M., Zuberbier T., Aberer W., Akdis C.A., Akdis M., Alberti M.R., Almeida R., Angles R., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Basagana X., Bedolla-Barajas M., Beghe B., Bel E.H., Bergmann K.C., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bouchard J., Boulet L.P., Bourret R., Braido F., Briedis V., Brightling C.E., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillot D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Castellano G., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Cortes-Grimaldo R.M., Corti F., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Dahlen S.E., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., Dedeu T., de Fatima Emerson M., De Vries G., De Martino B., de Paula Motta Rubini N., Deleanu D., Denburg J.A., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Eklund P., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Aymerich J., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., George C., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Hajjam J., Hernandez L., Hourihane J.O., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Jutel M., Kalyoncu A.F., Karjalainen J., Kardas P., Keith P.K., Khaltaev N., Kleine-Tebbe J., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Lauri D., Lavrut J., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Luna-Pech J.A., Maciej K., Magnan A., Maier D., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Medina-Avalos M.A., Melen E., Melo-Gomes E., Meltzer E.O., Mercier J., Miculinic N., Mihaltan F., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Monti R., Mora Bogado D., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Nadif R., Nalin M., Napoli L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Nyembue T.D., Odzhakova C., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Papi A., Passalacqua G., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Pohl W., Portejoie F., Pozzi A.C., Price D., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Sagara H., Sastre-Dominguez J., Scadding G.K., Scichilone N., Schmid-Grendelmeier P., Serpa F.S., Shamai S., Sierra M., Simons F.E.R., Siroux V., Skrindo I., Sole D., Somekh D., Sondermann M., Sova M., Sorensen M., Sorlini M., Spranger O., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., van Eerd M., van Ganse E., van Hague M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi M., Vicheva D., Vontetsianos T., Walker S., Werfel T., Westman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zernotti M.E., Zubrinich C., Zurkuhlen A., Bousquet, Jean, Hellings, Peter W., Agache, Ioana, Amat, Flore, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Clau, Bateman, Eric D., Bedbrook, Anna, Bennoor, Kazi, Bewick, Mickael, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brozek, Jan, Brussino, Luisa, Canonica, Giorgio W., Cardona, Victoria, Casale, Thoma, Cepeda Sarabia, Alfonso M., Chavannes, Niels H., Cecchi, Lorenzo, Correia de Sousa, Jaime, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, De Carlo, Giuseppe, De Feo, Giulia, Demoly, Pascal, Devillier, Philippe, Dykewicz, Mark S., El-Gamal, Yehia, Eller, Esben E., Fonseca, Joao A., Fontaine, Jean-Françoi, Fokkens, Wytske J., Guzmán, Maria-Antonieta, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan-Carlo, Just, Jocelyne, Kaidashev, Igor, Khaitov, Musa, Kalayci, Omer, Keil, Thoma, Klimek, Ludger, Kowalski, Marek L., Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Desiree, Laune, Daniel, Le, Lan T. T., Carlsen, Karin Lodrup, Lourenço, Olga, Mahboub, Bassam, Mair, Alpana, Menditto, Enrica, Milenkovic, Branislava, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Murray, Ruth, Naclerio, Robert, Namazova-Baranova, Leyla, Novellino, Ettore, O'Hehir, Robyn E., Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Onorato, Gabrielle L., Palkonen, Susanna, Panzner, Petr, Papadopoulos, Nikos G., Park, Hae-Sim, Paulino, Ema, Pawankar, Ruby, Pfaar, Oliver, Plavec, Davor, Popov, Ted A., Potter, Paul, Prokopakis, Emmanuel P., Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Samolinski, Boleslaw, Sanchez-Borges, Mario, Schunemann, Holger J., Sheikh, Aziz, Sisul, Juan-Carlo, Rajabian-Söderlund, Rojin, Sooronbaev, Talant, Stellato, Cristiana, To, Teresa, Todo-Bom, Ana-Maria, Tomazic, Peter-Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Aruna, Valovirta, Erkka, Ventura, Maria-Teresa, Wagenmann, Martin, Wang, De Yun, Wallace, Dana, Waserman, Susan, Wickman, Magnu, Yorgancioglu, Arzu, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, Zuberbier, Torsten, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Alberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosnic-Anticevich, C. S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillot, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Cardona, V., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda Sarabia, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Cruz, A. A., Custovic, A., Czarlewski, W., Dahlen, S. E., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fátima Emerson, M., De Feo, G., De Vries, G., De Martino, B., de Paula Motta Rubini, N., Deleanu, D., Demoly, P., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fokkens, W. J., Fonseca, J. A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Gálvez-Romero, J. L., Gamkrelidze, A., Garcia-Aymerich, J., García-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioğlu, B., Genova, S., George, C., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzmán, M. A., Haahtela, T., Hajjam, J., Hernández, L., Hourihane, J. O. 'B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ivancevich, J. C., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Klimek, L., Kowalski, M. L., Kuitunen, M., Kull, I., Kuna, P., Kupczyk, M., Kvedariene, V., Krzych-Fałta, E., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenço, O., Luna-Pech, J. A., Maciej, K., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M. A., Melén, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Monti, R., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mösges, R., Mota-Pinto, A., Moura Santo, P., Mullol, J., Münter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Palkonen, S., Panzner, P., Papadopoulos, N. G., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pépin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Mañas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimäki, J., Samolinski, B., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Serpa, F. S., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyriçá, J. N., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hague, M., Vandenplas, O., Ventura, M. T., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, M., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Laboratory of clinical immunology, Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia [Bilbao], Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hacettepe University = Hacettepe Üniversitesi, Mechanobiology Institute [Singapore] (MBI), National University of Singapore (NUS), Department of Clinical Epidemiology and Biostatistics and Medicine, McMaster University [Hamilton, Ontario], Department of Dermatology [Graz, Austria], Medical University Graz, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Ghent University Hospital, Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), IMIM-Hospital del Mar, Generalitat de Catalunya, University of Cape Town, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Centre de gérontologie, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Woolcock Institute of Medical Research [Sydney], The University of Sydney, Université Laval [Québec] (ULaval), Departments of Clinical Epidemiology and Biostatistics and Medicine [Ontario], Service greffe de moelle osseuse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Vall d'Hebron University Hospital [Barcelona], University of South Florida [Tampa] (USF), Università degli Studi di Firenze = University of Florence (UniFI), University of Michigan, Department of Atmospheric, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Russian State Medical University, Universidade do Porto, Instituto de Biologia Molecular e Celular (IBMC), UCB Pharma, Colombes, Hôpital Gui de Chauliac [CHU Montpellier], CHU Strasbourg, European Federation of Allergy (EFA), Airways Diseases Patients' Associations, Università degli Studi di Salerno = University of Salerno (UNISA), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Linköping University (LIU), Department of Dermatology and Allergy Centre, Odense University Hospital, Vilnius University [Vilnius], Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, Institut d'Electronique du Solide et des Systèmes (InESS), Centre National de la Recherche Scientifique (CNRS), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Center for Allergy and Immunology Research [Tbilisi], Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Swedish Meteorological and Hydrological Institute (SMHI), CORYSS-TESS, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Biologie des organismes marins et écosystèmes (BOME), Muséum national d'Histoire naturelle (MNHN)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), NRC Institute of immunology FMBA, Moscow Russian federation, Allergy and Asthma Center Westend, German Society for Otorhinolaryngology HNS, Rheinische Friedrich-Wilhelms-Universität Bonn, The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Medical University of Łódź (MUL), Hospital Medica Sur, Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Applied Physical Chemistry Laboratory (APCLab), Institute of Geophysics and Planetary Physics [Los Angeles] (IGPP), University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Institute of Oceanology [China], University of Beira Interior [Portugal] (UBI), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Pulmonary and allergy unit, American University of Sharjah-Rashid Hospital-Dubai Health Authority (DHA), Astrophysique Interprétation Modélisation (AIM (UMR7158 / UMR_E_9005 / UM_112)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), 'Federico II' University of Naples Medical School, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Allergy and Clinical Immunology Department, Hospital CUF Descobertas, Universität zu Köln = University of Cologne, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Section of Otolaryngology-Head & Neck Surgery (OHNS), University of Chicago, Department of Pharmacy Naples, Université de Naples, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Dept. of Electronic Engineering, Chubu University, Department of Otorhinolaryngology, Chiba University Hospital, Department of Allergology and Clinical Immunology, Charles University [Prague] (CU)-Medical Faculty in Pilsen, Department of Earth and Planetary Sciences [Cambridge, USA] (EPS), Harvard University, Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Department of Pediatrics, Nippon Medical School, Centre Hospitalier Universitaire [Grenoble] (CHU), Department of Otorhinolaryngology, Head and Neck Surgery [Mannheim, Germany], University Hospital Mannheim, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Children’s Hospital Srebrnjak [Zagreb, Croatia], Department of Physics [UMIST Manchester], University of Manchester Institute of Science and Technology (UMIST), Laboratori Nazionali del Sud (LNS), Getafe University Hospital, Madrid, Karl-Franzens-Universität Graz, Ecologie comportementale (EC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes (UR)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Allergy Asthma and Immunology [Haifa, Israel], Ha'Emek Medical Center, Afula-Rappaport Faculty of Medicine, University of Edinburgh, Medical University of Warsaw - Poland, Department of Allergy and Clinical Immunology [Caracas, Venezuela], Centro Médico Docente La Trinidad, Department of Computer Science [Haifa], University of Haifa [Haifa], Allergy and Respiratory Research Group, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), National Centre of Cardiology and Internal Medicine, Ministry of Health Kyrgyz Republic, Réseau National de Surveillance Aérobiologique (RNSA), Berkeley Seismological Laboratory, Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, Vilnius University Clinic of Children's Diseases, Suomen Terveystalo Allergy Clinic, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre d'EPistémologie et d'ERgologie Comparatives (CEPERC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institute for Climate and Atmospheric Science [Leeds] (ICAS), School of Earth and Environment [Leeds] (SEE), University of Leeds-University of Leeds, Nova Southeastern University (NSU), Department of Otolaryngology, National University of Singapore (NUS)-Yong Loo Lin School of Medicine, Sachs' Children's Hospital, IAES, Department of Pulmonology, Manisa Celal Bayar University, Center for Evolutionary and Theoretical Immunology [Albuquerque, New Mexico] (CETI), The University of New Mexico [Albuquerque], National Key State Laboratory for ThermoStructural Composites (TSCM), Northwestern Polytechnical University [Xi'an] (NPU), Respiratory and Allergic Diseases, University Clinic of Respiratory and Allergic Diseases Golnik, University Hospital of Cologne [Cologne], Supported by the European Innovation Partnership on Active and Healthy Ageing and POLLAR (EIT Health, European Union)., European Project: 643803,H2020,H2020-HCO-2014,PROEIPAHA(2015), UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidemiology of Allergic and Respiratory Diseases Department [Paris] (EPAR), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Université Pierre et Marie Curie - Paris 6 (UPMC), University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Salerno (UNISA), Institut de Physique du Globe de Paris (IPGP), Centre National de la Recherche Scientifique (CNRS)-Université de La Réunion (UR)-Université Paris Diderot - Paris 7 (UPD7)-IPG PARIS-Institut national des sciences de l'Univers (INSU - CNRS), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]-Epidemiology and Health Economics, Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN), University of California-University of California, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospital CUF-Descobertas, Universität zu Köln, Medical Faculty in Pilsen-Charles University in Prague - the First Faculty of Medicine, Harvard University [Cambridge], University of Genoa (UNIGE), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Graz, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université Claude Bernard Lyon 1 (UCBL), Centro Medico-Docente La Trinidad, Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Università degli studi di Napoli Federico II, Center for Evolutionary and theoretical Immunology, Biology, National Institute for Health Research, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Karl-Franzens-Universität [Graz, Autriche], Department of Dermatology, Allergology and Venereology, Clinicum, University of Helsinki, Children's Hospital, Faculty of Law, HUS Children and Adolescents, HUS Inflammation Center, University Hospitals Leuven [Leuven], Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, University of Zürich [Zürich] (UZH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of South Florida (USF), Università degli Studi di Firenze = University of Florence [Firenze], Laboratoire Magmas et Volcans (LMV), Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Universidade do Porto [Porto], Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin -Epidemiology and Health Economics, Université Pierre et Marie Curie - Paris 6 (UPMC)-Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Sondra, CentraleSupélec, Université Paris-Saclay (COmUE) (SONDRA), ONERA-CentraleSupélec-Université Paris Saclay (COmUE), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), RNSA, Centre d'EPistémologie et d'ERgologie Comparatives - UMR 7304 (CEPERC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), National Institute for Nuclear Physics (INFN), Université Laval, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Università degli Studi di Firenze [Firenze], University of Salerno (UNISA), Centre National de la Recherche Scientifique (CNRS)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), École normale supérieure - Paris (ENS Paris)-Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université de Rennes 1 (UR1), Universidade do Minho, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, uBibliorum, and Internal Medicine

Subjects
Allergy, Medicina Básica [Ciências Médicas], asthma -- guideline, Allergic asthma, DECISION-MAKING, Allergic Rhinitis and Its Impact on Asthma, GUIDELINES, Medical and Health Sciences, Medical Records, 0302 clinical medicine, Health care, Immunology and Allergy, 030212 general & internal medicine, asthma, Change management, rhinitis, Immunology, MASK-RHINITIS, ComputingMilieux_MISCELLANEOUS, Rinitis, mobilne aplikacije, upravljanje sprememb, Medical record, GLOBAL STRATEGY, WORK PRODUCTIVITY, Telemedicine, mobile applications, 3. Good health, Asma alérgica, rhiniti, 1107 Immunology, Ciências Médicas::Medicina Básica, klinične poti, allergic -- guideline, Life Sciences & Biomedicine, Human, PATIENT PARTICIPATION, Allergic Rhinitis, medicine.medical_specialty, animal structures, multimorbidity, EUROPEAN INNOVATION PARTNERSHIP, Change Management, [object Object], Settore MED/10 - Malattie Dell'Apparato Respiratorio, Asthma/diagnosis, CHRONIC DISEASES, MACVIA-ARIA, 03 medical and health sciences, medicine, multimorbidnost, QUALITY, Humans, critical pathways, astma -- smernica, Patient participation, Asma, udc:616.2, Asthma, Science & Technology, ARIA, business.industry, Multimorbidity, Rhinitis, Allergic, Settore MED/09 - MEDICINA INTERNA, change management, Mobile Airways Sentinel Network (MASK) Study Group, Guideline, ta3121, medicine.disease, Rinite alérgica, Rhinitis, Allergic/diagnosis, Integrated care, alergijski rinitis -- smernica, Allergic Rhinitis and Its Impact on Asthma, asthma, Change management, rhinitis, Immunology and Allergy, Immunology, 030228 respiratory system, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Medical Record, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Impact on Asthma
Abstract

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional., EAACI -European Academy of Allergy and Clinical Immunology(undefined), info:eu-repo/semantics/acceptedVersion

Published
2018

23. Allergy-related diseases and recurrent abdominal pain during childhood - a birth cohort study

Author

Magnus Simren, Åsa Neuman, Ola Olén, Erik Melén, Marit Westman, B. Koopmann, Natalia Ballardini, Inger Kull, Anna Bergström, and Jonas F. Ludvigsson

Subjects
Male, medicine.medical_specialty, Allergy, MEDLINE, Comorbidity, medicine.disease_cause, Gastroenterology, Cohort Studies, Recurrence, Internal medicine, Hypersensitivity, Prevalence, medicine, Humans, Pharmacology (medical), Child, Sweden, Hepatology, business.industry, Infant, Immune dysregulation, medicine.disease, Recurrent abdominal pain, Pathophysiology, Abdominal Pain, Child, Preschool, Female, business, Birth cohort, Cohort study
Abstract

Allergy and immune dysregulation may have a role in the pathophysiology of recurrent abdominal pain of functional origin, but previous studies of allergy-related diseases and abdominal pain have contradictory results.To examine the association between allergy-related diseases or sensitisation during childhood and abdominal pain at age 12 years.In this birth cohort study of 4089 children, parents answered questionnaires regarding asthma, allergic rhinitis, eczema and food hypersensitivity ('allergy-related diseases') at ages 0,1,2,4,8 and 12 years. Blood for analyses of allergen-specific IgE was sampled at 4 and 8 years. At 12 years, the children answered questions regarding abdominal pain. Children with coeliac disease or inflammatory bowel disease were excluded. Associations were examined using multivariable logistic regression.Among 2610 children with complete follow-up, 9% (n = 237) reported abdominal pain at 12 years. All allergy-related diseases were associated with concurrent abdominal pain at 12 years and the risk increased with increasing number of allergy-related diseases (P for trend0.001). Asthma at 1 and 2 years and food hypersensitivity at 8 years were significantly associated with abdominal pain at 12 years. There was an increased risk of abdominal pain at 12 years in children sensitised to food allergens at 4 or 8 years, but in stratified analyses, this was confined to children whose parents had not reported food hypersensitivity at time of sensitisation.Allergy-related diseases as well as sensitisation to food allergens were associated with an elevated risk of abdominal pain, and the risk increased with the number of allergy-related diseases.

Published
2014

24. Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts

Author

Anna Asarnoj, Carl Hamsten, Marianne van Hage, Marit Westman, and Magnus Wickman

Subjects
0301 basic medicine, Allergy, Adolescent, Immunology, Disease, medicine.disease_cause, Allergic sensitization, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Allergen, Population Groups, Immune Tolerance, Immunology and Allergy, Medicine, Humans, Early childhood, Child, Sensitization, business.industry, Allergens, Immunoglobulin E, medicine.disease, Asthma, Tolerance induction, 030104 developmental biology, medicine.anatomical_structure, 030228 respiratory system, Food, Life course approach, Desensitization, Psychologic, business, Food Hypersensitivity
Abstract

Allergic sensitization is a risk factor for developing IgE-mediated allergic diseases, which are a major cause of chronic illness world-wide. The introduction of allergen molecules to the field of allergy diagnostics has allowed dissecting the IgE response on a molecular level to pinpoint the specific disease-causing allergens. Studying birth cohorts is an essential tool for understanding the development and life course of allergy, enabling the possibility to design preventive strategies. Here we review the evolution of sensitization using data from some of the large European birth cohort studies. Differences and similarities between sensitization to food and various sources of inhalant allergens are discussed and allergen molecules of importance in early childhood predicting disease in adolescence are highlighted. Finally, we discuss windows of opportunity where intervention could be considered and address possible preventive strategies.

Published
2017

25. Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps

Author

Karin Jonstam, Cecile T.J. Holweg, Claus Bachert, Marit Westman, and Gabriele Holtappels

Subjects
Adult, Male, Adolescent, Chronic rhinosinusitis, Immunology, Inflammation, Periostin, Immunoglobulin E, Severity of Illness Index, Lebrikizumab, Enterotoxins, Young Adult, 03 medical and health sciences, Nasal Polyps, 0302 clinical medicine, Severity of illness, Humans, Immunology and Allergy, Medicine, Nasal polyps, Sinusitis, 030223 otorhinolaryngology, Aged, Rhinitis, Asthma, biology, business.industry, Middle Aged, medicine.disease, 030228 respiratory system, Chronic Disease, biology.protein, Female, Interleukin-5, medicine.symptom, business, Cell Adhesion Molecules, Biomarkers, medicine.drug
Published
2017

26. Fish and polyunsaturated fat intake and development of allergic and nonallergic rhinitis

Author

Anna Bergström, Jessica Magnusson, Alicja Wolk, Niclas Håkansson, Magnus Wickman, Inger Kull, Erik Melén, and Marit Westman

Subjects
Adolescent, Immunology, Physiology, Immunoglobulin E, Cohort Studies, Eating, Nonallergic rhinitis, children, Fish Products, medicine, Vitamin D and neurology, Immunology and Allergy, Oily fish, Animals, Humans, Cumulative incidence, Prospective Studies, Vitamin D, Prospective cohort study, Child, fish, 2. Zero hunger, chemistry.chemical_classification, allergic rhinitis, biology, business.industry, nonallergic rhinitis, Odds ratio, medicine.disease, Rhinitis, Allergic, chemistry, biology.protein, Fatty Acids, Unsaturated, BAMSE, fatty acid, diet, business, Polyunsaturated fatty acid
Abstract

BackgroundRhinitis is one of the most common diseases in childhood. Fish, polyunsaturated fatty acid (PUFA), and vitamin D intakes have been hypothesized to affect the risk of allergic disease; however, it is unclear whether these are linked to the development of rhinitis.ObjectiveWe sought to assess potential associations between consumption of fish, dietary n-3 and n-6 PUFAs, and vitamin D at age 8 years and development of allergic rhinitis (AR) and nonallergic rhinitis (NAR) between the ages of 8 and 16 years.MethodsWe included 1970 participants from a birth cohort. Data on dietary intake was obtained from a food frequency questionnaire at age 8 years. The rhinitis definition was based on questionnaires and IgE measures.ResultsThe prevalence of rhinitis symptoms at age 8 years was 19% (n = 380). Among the 1590 children without rhinitis symptoms at age 8 years, 21% (n = 337) had AR between ages 8 and 16 years, and 15% (n = 236) had NAR. Regular intake of oily fish and higher long-chain n-3 PUFA intake were associated with a reduced risk of cumulative incidence of NAR (adjusted odds ratio, 0.52 [95% CI, 0.32-0.87] for oily fish; odds ratio, 0.45 [95% CI, 0.30-0.67] for highest vs lowest tertile of long-chain n-3 PUFAs; P trend

Published
2014

27. Mechanisms of the Development of Allergy (MeDALL) : Introducing novel concepts in allergy phenotypes

Author

Isabelle Pin, Stefano Guerra, Cynthia Hohmann, Marit Westman, Mariona Pinart, Jordi Mestres, Martijn C. Nawijn, Tari Haahtela, Dirkje S. Postma, Torsten Zuberbier, Kalus Wenzel, Mika J. Mäkelä, Fanny Rancière, Karin C. Lødrup Carlsen, Mirela Curin, Dieter Maier, Stephane Ballereau, Johan Pellet, Cezmi A. Akdis, Claus Bachert, Erik Melén, Emilie Burte, Bénédicte Jacquemin, Jean Bousquet, Anne Cambon-Thomsen, Christian Lupinek, I. Skrindo, Mübeccel Akdis, Rachel Nadif, Bert Brunekreef, Judith Garcia-Aymerich, Jonathan M. Coquet, Valérie Siroux, Inger Kull, Peter Mowinckel, Bart N. Lambrecht, Renata Kiss, Anna Bedbrook, Ferran Ballester, Kai-Håkon Carlsen, Yvan Saeys, Raphaëlle Varraso, Emmanuelle Rial-Sebbag, Giuseppe De Carlo, Sibylle Koletzko, Maria Pia Fantini, Joachim Heinrich, Jordi Sunyer, Andrea von Berg, Gerard H. Koppelman, Theresa Keller, Vergard Hovland, John Wright, Nicolas Lemonnier, Josep M. Antó, Marta Benet, Rudolf Valenta, Irina Lehmann, Susanne Lau, Francesco Forastiere, Isabelle Momas, Niklas Andersson, Albert Arno, Pascal Demoly, Jocelyne Just, Anna Bergström, Charles Auffray, Henriette A. Smit, Delphine Smagghe, Manolis Kogevinas, Anna Asarnoj, Marie Standl, Daniela Porta, I. Annesi-Maesano, Martijn J. Schuijs, Ulrike Gehring, Mathies Torrent, Thomas Keil, Christina Tischer, Cheng-Jian Xu, Esben Eller, Marek L. Kowalski, Carsten Bindslev-Jensen, Leda Chatzi, Magnus Wickman, Natalia Ballardini, Leena von Hertzen, Xavier Basagaña, Anto, Josep M., Bousquet, Jean, Akdis, Mubeccel, Auffray, Charle, Keil, Thoma, Momas, Isabelle, Postma, Dirkje S., Valenta, Rudolf, Wickman, Magnu, Cambon-Thomsen, Anne, Haahtela, Tari, Lambrecht, Bart N., Lodrup Carlsen, Karin C., Koppelman, Gerard H., Sunyer, Jordi, Zuberbier, Torsten, Annesi-Maesano, Isabelle, Arno, Albert, Bindslev-Jensen, Carsten, De Carlo, Giuseppe, Forastiere, Francesco, Heinrich, Joachim, Kowalski, Marek L., Maier, Dieter, Melén, Erik, Smit, Henriette A., Standl, Marie, Wright, John, Asarnoj, Anna, Benet, Marta, Ballardini, Natalia, Garcia-Aymerich, Judith, Gehring, Ulrike, Guerra, Stefano, Hohmann, Cynthia, Kull, Inger, Lupinek, Christian, Pinart, Mariona, Skrindo, Ingebjorg, Westman, Marit, Smagghe, Delphine, Akdis, Cezmi, Andersson, Nikla, Bachert, Clau, Ballereau, Stephane, Ballester, Ferran, Basagana, Xavier, Bedbrook, Anna, Bergstrom, Anna, von Berg, Andrea, Brunekreef, Bert, Burte, Emilie, Carlsen, Kai-Hakon, Chatzi, Leda, Coquet, Jonathan M., Curin, Mirela, Demoly, Pascal, Eller, Esben, Fantini, Maria Pia, von Hertzen, Leena, Hovland, Vergard, Jacquemin, Benedicte, Just, Jocelyne, Keller, Theresa, Kiss, Renata, Kogevinas, Manoli, Koletzko, Sibylle, Lau, Susanne, Lehmann, Irina, Lemonnier, Nicola, Mäkelä, Mika, Mestres, Jordi, Mowinckel, Peter, Nadif, Rachel, Nawijn, Martijn C., Pellet, Johan, Pin, Isabelle, Porta, Daniela, Rancière, Fanny, Rial-Sebbag, Emmanuelle, Saeys, Yvan, Schuijs, Martijn J., Siroux, Valerie, Tischer, Christina G., Torrent, Mathie, Varraso, Raphaelle, Wenzel, Kalu, Xu, Cheng-Jian, dIRAS RA-2, LS IRAS EEPI ME (Milieu epidemiologie), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), European Institute for Systems Biology and Medicine (EISBM), Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Centre de l'Asthme et des Allergies [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut Albert Bonniot, Département de pédiatrie, CHU Grenoble-Hôpital Michallon, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
0301 basic medicine, Allergy, Genome-wide association study, Comorbidity, Immunoglobulin E, medicine.disease_cause, Cohort Studies, Translational Research, Biomedical, 0302 clinical medicine, Allergen, REGULATORY B-CELLS, PRECISION MEDICINE, Medicine, BIRTH COHORT INFANTS, ATOPIC-DERMATITIS, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Child, media_common, biology, atopic dermatitis, Atopic dermatitis, 3. Good health, Europe, Multicenter Study, CHRONIC RESPIRATORY-DISEASES, rhiniti, Phenotype, INNER-CITY CHILDREN, Biomarker (medicine), Female, atopic dermatiti, Adolescent, EUROPEAN INNOVATION PARTNERSHIP, Immunology, review, 03 medical and health sciences, EARLY-LIFE, Young Adult, rhinitis, Asthma, Atopic Dermatitis, Rhinitis, Hypersensitivity, Journal Article, media_common.cataloged_instance, Animals, Humans, European union, MOUNTAIN CEDAR POLLINOSIS, business.industry, Gene Expression Profiling, CHILDHOOD ASTHMA, Allergens, medicine.disease, allergy, 030104 developmental biology, 030228 respiratory system, biology.protein, Immunization, business, Genome-Wide Association Study
Abstract

Asthma, rhinitis, and eczema are complex diseases with multiple genetic and environmental factors interlinked through IgE-associated and non–IgE-associated mechanisms. Mechanisms of the Development of ALLergy (MeDALL; EU FP7-CP-IP; project no: 261357; 2010-2015) studied the complex links of allergic diseases at the clinical and mechanistic levels by linking epidemiologic, clinical, and mechanistic research, including invivo and invitro models. MeDALL integrated 14 European birth cohorts, including 44,010 participants and 160 cohort follow-ups between pregnancy and age 20years. Thirteen thousand children were prospectively followed after puberty by using a newly standardized MeDALL Core Questionnaire. Amicroarray developed for allergen molecules with increased IgE sensitivity was obtained for 3,292 children. Estimates of air pollution exposure from previous studies were available for 10,000 children. Omics data included those from historical genome-wide association studies (23,000 children) and DNA methylation (2,173), targeted multiplex biomarker (1,427), andtranscriptomic (723) studies. Using classical epidemiology and machine-learning methods in 16,147 children aged 4years and 11,080 children aged 8years, MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of multimorbidity was attributable to IgE sensitization. MeDALL has proposed a new vision of multimorbidity independent of IgE sensitization, and has shown that monosensitization and polysensitization represent 2 distinct phenotypes. The translational component of MeDALL is shown by the identification of a novel allergic phenotype characterized by polysensitization and multimorbidity, which is associated with the frequency, persistence, and severity of allergic symptoms. The results of MeDALL will help integrate personalized, predictive, preventative, and participatory approaches in allergic diseases.

Published
2017

28. Natural course and comorbidities of allergic and nonallergic rhinitis in children

Author

Elina Toskala, Anna Asarnoj, Marit Westman, Marianne van Hage, Magnus Wickman, Pär Stjärne, and Inger Kull

Subjects
Male, Allergy, medicine.medical_specialty, Rhinitis, Allergic, Perennial, Immunology, Comorbidity, Immunoglobulin E, medicine.disease_cause, Allergic sensitization, Cohort Studies, Nonallergic rhinitis, Allergen, Oral allergy syndrome, Food allergy, medicine, Immunology and Allergy, Humans, Child, Asthma, Rhinitis, Sweden, biology, business.industry, Allergens, medicine.disease, Dermatology, Child, Preschool, biology.protein, Female, business
Abstract

Background Not much data are available from large, unselected, birth cohort studies on the natural course and comorbidities of rhinitis in children. Objective To study phenotypes of rhinitis in relation to the natural course and comorbidities of allergic diseases in preschool-age and early school-age children. Methods We analyzed data from a birth cohort of 2024 children, for whom information on IgEs against 8 common inhaled allergens was available, collected at age 4 and 8 years. The children were assigned to groups of allergic rhinitis (rhinitis with sensitization to allergens), nonallergic rhinitis (rhinitis without sensitization), allergic sensitization but no rhinitis, or neither rhinitis nor sensitization. Results The proportion of children with allergic rhinitis increased from 5% to 14% from age 4 to 8 years, whereas the proportion of children with nonallergic rhinitis decreased slightly over the same period of development, from 8% to 6%. Of the children with allergic rhinitis when they were 4 years old, 12% underwent remission by the time they were 8 years old; of the children with nonallergic rhinitis, 73% underwent remission during this period of development. Among 4-year-olds without rhinitis who were sensitized to allergen, 56% had allergic rhinitis when they were 8 years old. Among 4- and 8-year-olds, allergic rhinitis and nonallergic rhinitis were associated with asthma, eczema, and food hypersensitivity. Twenty-five percent of 8-year-olds with allergic rhinitis also had oral allergy syndrome. Conclusions Fewer preschool-age children with allergic rhinitis undergo remission than do those with nonallergic rhinitis. Sensitization to inhaled allergens at an early age (4 years) precedes the development of allergic rhinitis, whereas symptoms of rhinitis do not. Oral allergy syndrome is common among 8-year-olds with allergic rhinitis.

Published
2010

29. Chronic rhinosinusitis is rare but bothersome in adolescents from a Swedish population-based cohort

Author

Elina Toskala, Magnus Wickman, Mats Holmström, Anna Bergström, Inger Kull, Lars-Olaf Cardell, Pär Stjärne, and Marit Westman

Subjects
Male, Sweden, Pediatrics, medicine.medical_specialty, Adolescent, business.industry, Chronic rhinosinusitis, Immunology, Cohort Studies, Swedish population, Surveys and Questionnaires, Chronic Disease, Cohort, Prevalence, Quality of Life, Humans, Immunology and Allergy, Medicine, Female, Sinusitis, business, Rhinitis
Published
2015

30. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence

Author

Pär Stjärne, Alexandra Baar, Magnus Wickman, Niklas Andersson, Anna Bergström, Sandra Pahr, Marianne van Hage, Josep M. Antó, Kaj-Håkon Carlsen, Christian Lupinek, Rudolf Valenta, Marit Westman, Jean Bousquet, Karin C. Lødrup Carlsen, and Mats Holmström

Subjects
Allergy, Adolescent, Immunology, Cross Reactions, medicine.disease_cause, Immunoglobulin E, Cross-reactivity, Article, Cohort Studies, Allergen, Oral allergy syndrome, Seroepidemiologic Studies, medicine, Cluster Analysis, Humans, Immunology and Allergy, Child, Sweden, biology, business.industry, Incidence, Incidence (epidemiology), Age Factors, Odds ratio, Antigens, Plant, Prognosis, medicine.disease, Rhinitis, Allergic, Child, Preschool, Cohort, biology.protein, business
Abstract

BACKGROUND: Component-resolved diagnosis might improve the prediction of future allergy in young children. OBJECTIVE: We sought to investigate the association between IgE reactivity to the pathogenesis-related class 10 (PR-10) protein family and allergic rhinitis to birch pollen (AR(bp)) from early childhood up to age 16 years. METHOD: Questionnaire data and sera obtained at 4, 8, and 16 years of age from the Barn/Children Allergi/Allergy Milieu Stockholm Epidemiologic (BAMSE) study birth cohort were used. Sera from 764 children were analyzed for IgE reactivity to 9 PR-10 allergen proteins at the 3 time points by using an allergen chip based on ISAC technology. AR(bp) was defined as upper airway symptoms during birch pollen exposure. RESULTS: IgE reactivity to Bet v 1 was found in 12%, 17%, and 25% of children at 4, 8, and 16 years of age. IgE reactivity of PR-10 proteins showed a hierarchic intrarelationship: Bet v 1 > Mal d 1 > Cor a 1.04 > Ara h 8 > Pru p 1 > Aln g 1 > Api g 1 > Act d 8 > Gly m 4. There was an increased risk of incidence and persistence of AR(bp) up to age 16 years with increasing levels of Bet v 1–specific IgE or increasing numbers of IgE-reactive PR-10 proteins at 4 years. Children with severe AR(bp) at age 16 years had higher levels of Bet v 1–specific IgE at age 4 years compared with children with mild symptoms. CONCLUSION: AR(bp) at age 16 years can be predicted by analysis of IgE reactivity to PR-10 proteins in early childhood. (J Allergy Clin Immunol 2015;135:1199-206.)

Published
2015

31. Associations between the 17q21 region and allergic rhinitis in 5 birth cohorts

Author

Johan C. de Jongste, Marie Standl, Elaine Fuertes, Gerard H. Koppelman, Carla M. T. Tiesler, Anita L. Kozyrskyj, Moira Chan-Yeung, Erik Melén, Marit Westman, Cilla Söderhäll, Michael Brauer, Allan B. Becker, Göran Pershagen, Nathalie Acevedo, Andrew J. Sandford, F. Nicole Dijk, Juha Kere, Dirkje S. Postma, Christopher Carlsten, Melanie Waldenberger, Joachim Heinrich, Research Programs Unit, Research Programme for Molecular Neurology, Department of Medical and Clinical Genetics, Public Health, Pediatrics, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
medicine.medical_specialty, education, Immunology, Population, MEDLINE, Genome-wide association study, VARIANTS, Polymorphism, Single Nucleotide, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, DESIGN, Polymorphism (computer science), Internal medicine, Humans, Immunology and Allergy, Medicine, Genetic Predisposition to Disease, Genetic Association Studies, METAANALYSIS, POPULATION, 030304 developmental biology, Asthma, RISK, 0303 health sciences, education.field_of_study, business.industry, medicine.disease, Rhinitis, Allergic, PREVENTION, 030228 respiratory system, ASTHMA, 3111 Biomedicine, business, Birth cohort, Chromosomes, Human, Pair 17, Genome-Wide Association Study, Cohort study
Abstract

Non

Published
2015

33. Resolved allergen‐specific IgE sensitization among females and early poly‐sensitization among males impact IgE sensitization up to age 24 years

Author

Magnus P. Borres, Marit Westman, Erik Melén, Göran Pershagen, Marianne van Hage, Natalia Ballardini, Catarina Almqvist, Niklas Andersson, Anna Bergström, Inger Kull, Anna Asarnoj, and Antonis Georgellis

Subjects
Male, Adolescent, Immunology, Young Adult, 03 medical and health sciences, Dogs, Sex Factors, 0302 clinical medicine, medicine, Animals, Humans, Immunology and Allergy, Antigens, Dermatophagoides, Horses, Longitudinal Studies, Child, Ige sensitization, Allergen specific IgE, Betula, Sensitization, 030304 developmental biology, 0303 health sciences, business.industry, Rhinitis, Allergic, Seasonal, Allergens, Immunoglobulin E, medicine.anatomical_structure, Artemisia, 030228 respiratory system, Child, Preschool, Phleum, Cats, Female, business, Cladosporium, Food Hypersensitivity
Full Text
View/download PDF

34. Prevalence and early‐life risk factors for tree nut sensitization and allergy in young adults

Author

Caroline Nilsson, Sandra G Tedner, Jon R Konradsen, Marit Westman, Jessica Bager, Inger Kull, Magnus P. Borres, Niklas Andersson, Erik Melén, Anna Bergström, Marianne van Hage, Natalia Ballardini, and Anna Asarnoj

Subjects
Nut, Adult, Allergy, medicine.medical_specialty, Immunology, Population, Allergic sensitization, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, food, Risk Factors, medicine, Prevalence, Immunology and Allergy, Humans, Nuts, education, Sensitization, 030304 developmental biology, 2. Zero hunger, 0303 health sciences, education.field_of_study, business.industry, digestive, oral, and skin physiology, food and beverages, Allergens, medicine.disease, Dermatology, food.food, 3. Good health, medicine.anatomical_structure, 030228 respiratory system, Egg allergy, Child, Preschool, Tree nut allergy, Nut Hypersensitivity, business, Brazil nut
Abstract

Background Tree nut allergy may cause anaphylaxis. There are limited population-based studies on prevalence and early-life risk factors. Methods We evaluated the prevalence of reported symptoms and allergic sensitization to tree nuts at age 24 years in the BAMSE population-based cohort study and assessed early-life factors associated with the development of tree nut allergy. We estimated tree nut allergy prevalence, by analysing questionnaire data on tree nut ingestion and symptoms at age 12, 16 and 24 years, and IgE sensitization at age 24 years to hazelnut, walnut, pecan, cashew, pistachio, Brazil nut, almond extracts and allergen molecules Cor a 1, 9, 14 (hazelnut), Jug r 1 (walnut) and Ana o 3 (cashew). We evaluated eczema, asthma, food allergies, inherited risk of allergy and gender as potential early-life risk factors. Results Data were available for 2215/4089 (54%) BAMSE study participants, for estimation of the prevalence of tree nut sensitization (21.2%), tree nut allergy symptoms (9.8%) and combined sensitization and symptoms (7.9%, 2.1% for storage protein sensitization and symptoms, 4.3% for any sensitization and non-mild symptoms). Sixty-three per cent of sensitized individuals (295/470) were asymptomatic, but only 76/470 (16%) storage protein sensitized individuals. Egg allergy (ORadj 8.50 95% CI 2.15-33.6), eczema (ORadj 2.53 95% CI 1.21-5.32) and asthma (ORadj 5.59 95% CI 2.35-13.3)) at pre-school age were associated with future development of tree nut symptoms and storage protein sensitization. At age 24 years, tree nut allergy was associated with current eczema and with markers of current asthma severity. Sensitization to storage proteins was more strongly associated with symptoms than sensitization to whole extract for all tree nuts evaluated. Conclusions In this Swedish cohort, we found tree nut whole extract sensitization is common but usually asymptomatic. Storage protein sensitization is a more reliable indicator of tree nut symptoms. Tree nut allergy is associated with early onset, persistent and severe atopic disease.

Full Text
View/download PDF

35. Chronic rhinosinusitis in adolescence is a rare but bothersome condition - data from a Swedish population based cohort

Author

Lars-Olaf Cardell, Elina Toskala, Mats Holmström, Marit Westman, Magnus Wickman, Inger Kull, Anna Bergström, and Pär Stjärne

Subjects
Pulmonary and Respiratory Medicine, Disease specific, Pediatrics, medicine.medical_specialty, business.industry, Chronic rhinosinusitis, Immunology, Bioinformatics, Test (assessment), Swedish population, Sino nasal outcome test, Poster Presentation, Cohort, Olfactory threshold, otorhinolaryngologic diseases, Immunology and Allergy, Medicine, business, Birth cohort
Abstract

Method We used 3112 16-year-olds from a Swedish birth cohort called BAMSE. The adolescents who fulfilled the criteria of CRS according to the European Position Paper on Rhinosinusitis (EPOS) in a questionnaire, was contacted by telephone to verify the diagnosis. Those with ongoing symptoms were invited for a clinical follow up with nasal endoscopy, olfactory threshold test (Sniffin’ sticks) and the disease specific quality-of-life (QoL) questionnaire SNOT22 (Sino Nasal Outcome Test 22). QoL was compared to those without CRS with the generic EQ-5D VAS.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results